These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 1354355

  • 1. Carboxyl-terminal deletion and point mutations decrease the transforming potential of the activated rat neu oncogene product.
    Mikami Y, Davis JG, Dobashi K, Dougall WC, Myers JN, Brown VI, Greene MI.
    Proc Natl Acad Sci U S A; 1992 Aug 15; 89(16):7335-9. PubMed ID: 1354355
    [Abstract] [Full Text] [Related]

  • 2. The transforming potential of the c-erbB-2 protein is regulated by its autophosphorylation at the carboxyl-terminal domain.
    Akiyama T, Matsuda S, Namba Y, Saito T, Toyoshima K, Yamamoto T.
    Mol Cell Biol; 1991 Feb 15; 11(2):833-42. PubMed ID: 1671296
    [Abstract] [Full Text] [Related]

  • 3. Biochemical comparisons of the normal and oncogenic forms of insect cell-expressed neu tyrosine kinases.
    Guy PM, Carraway KL, Cerione RA.
    J Biol Chem; 1992 Jul 15; 267(20):13851-6. PubMed ID: 1352772
    [Abstract] [Full Text] [Related]

  • 4. A chimeric EGF-R-neu proto-oncogene allows EGF to regulate neu tyrosine kinase and cell transformation.
    Lehväslaiho H, Lehtola L, Sistonen L, Alitalo K.
    EMBO J; 1989 Jan 15; 8(1):159-66. PubMed ID: 2565807
    [Abstract] [Full Text] [Related]

  • 5. The role of non-ras transforming genes in chemical carcinogenesis.
    Cooper CS.
    Environ Health Perspect; 1991 Jun 15; 93():33-40. PubMed ID: 1685444
    [Abstract] [Full Text] [Related]

  • 6. Absence of autophosphorylation site Y882 in the p185neu oncogene product correlates with a reduction of transforming potential.
    Zhang HT, O'Rourke DM, Zhao H, Murali R, Mikami Y, Davis JG, Greene MI, Qian X.
    Oncogene; 1998 Jun 04; 16(22):2835-42. PubMed ID: 9671404
    [Abstract] [Full Text] [Related]

  • 7. Constitutively activated neu oncoprotein tyrosine kinase interferes with growth factor-induced signals for gene activation.
    Lehtola L, Sistonen L, Koskinen P, Lehväslaiho H, Di Renzo MF, Comoglio PM, Alitalo K.
    J Cell Biochem; 1991 Jan 04; 45(1):69-81. PubMed ID: 1706346
    [Abstract] [Full Text] [Related]

  • 8. An oncogenic point mutation confers high affinity ligand binding to the neu receptor. Implications for the generation of site heterogeneity.
    Ben-Levy R, Peles E, Goldman-Michael R, Yarden Y.
    J Biol Chem; 1992 Aug 25; 267(24):17304-13. PubMed ID: 1355090
    [Abstract] [Full Text] [Related]

  • 9. Mutational analysis of conserved residues in the tyrosine kinase domain of the human trk oncogene.
    Mitra G.
    Oncogene; 1991 Dec 25; 6(12):2237-41. PubMed ID: 1837350
    [Abstract] [Full Text] [Related]

  • 10. Neu and its ligands: from an oncogene to neural factors.
    Peles E, Yarden Y.
    Bioessays; 1993 Dec 25; 15(12):815-24. PubMed ID: 7908191
    [Abstract] [Full Text] [Related]

  • 11. Downstream signal transduction defects that suppress transformation in two revertant cell lines expressing activated rat neu oncogene.
    Reardon DB, Hung MC.
    J Biol Chem; 1993 Aug 25; 268(24):18136-42. PubMed ID: 7688739
    [Abstract] [Full Text] [Related]

  • 12. The biological activity of the human epidermal growth factor receptor is positively regulated by its C-terminal tyrosines.
    Helin K, Velu T, Martin P, Vass WC, Allevato G, Lowy DR, Beguinot L.
    Oncogene; 1991 May 25; 6(5):825-32. PubMed ID: 1646987
    [Abstract] [Full Text] [Related]

  • 13. Protein tyrosine kinase activities of the epidermal growth factor receptor and ErbB proteins: correlation of oncogenic activation with altered kinetics.
    Nair N, Davis RJ, Robinson HL.
    Mol Cell Biol; 1992 May 25; 12(5):2010-6. PubMed ID: 1314948
    [Abstract] [Full Text] [Related]

  • 14. p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity.
    Stern DF, Heffernan PA, Weinberg RA.
    Mol Cell Biol; 1986 May 25; 6(5):1729-40. PubMed ID: 2878363
    [Abstract] [Full Text] [Related]

  • 15. A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway.
    Ben-Levy R, Paterson HF, Marshall CJ, Yarden Y.
    EMBO J; 1994 Jul 15; 13(14):3302-11. PubMed ID: 7913890
    [Abstract] [Full Text] [Related]

  • 16. Tissue-specific transformation by epidermal growth factor receptor: a single point mutation within the ATP-binding pocket of the erbB product increases its intrinsic kinase activity and activates its sarcomagenic potential.
    Shu HK, Pelley RJ, Kung HJ.
    Proc Natl Acad Sci U S A; 1990 Dec 15; 87(23):9103-7. PubMed ID: 1979168
    [Abstract] [Full Text] [Related]

  • 17. Dissecting the activating mutations in v-erbB of avian erythroblastosis virus strain R.
    Shu HK, Pelley RJ, Kung HJ.
    J Virol; 1991 Nov 15; 65(11):6173-80. PubMed ID: 1681117
    [Abstract] [Full Text] [Related]

  • 18. Disease tropism of c-erbB: effects of carboxyl-terminal tyrosine and internal mutations on tissue-specific transformation.
    Pelley RJ, Maihle NJ, Boerkoel C, Shu HK, Carter TH, Moscovici C, Kung HJ.
    Proc Natl Acad Sci U S A; 1989 Sep 15; 86(18):7164-8. PubMed ID: 2550929
    [Abstract] [Full Text] [Related]

  • 19. Differential processing and turnover of the oncogenically activated neu/erb B2 gene product and its normal cellular counterpart.
    Huang SS, Koh HA, Konish Y, Bullock LD, Huang JS.
    J Biol Chem; 1990 Feb 25; 265(6):3340-6. PubMed ID: 1968062
    [Abstract] [Full Text] [Related]

  • 20. The role of autophosphorylation in modulation of erbB-2 transforming function.
    Segatto O, Lonardo F, Pierce JH, Bottaro DP, Di Fiore PP.
    New Biol; 1990 Feb 25; 2(2):187-95. PubMed ID: 1982072
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.